GLP-1R Actions on Muscle and the Skeleton
Phase PHASE4 · ACTIVE_NOT_RECRUITING · Sponsor: Pennington Biomedical Research Center
Tirzepatide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
ClinicalTrials.gov (21)
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Phase PHASE1 · RECRUITING · Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase PHASE2 · RECRUITING · Sponsor: Eli Lilly and Company
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase PHASE3 · COMPLETED · Sponsor: Novo Nordisk A/S
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Phase PHASE2 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Phase PHASE2 · RECRUITING · Sponsor: T. John Winhusen, PhD
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Phase PHASE2 · RECRUITING · Sponsor: Eli Lilly and Company
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
Tirzepatide in MetALD
Phase PHASE2 · RECRUITING · Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: Mayo Clinic
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Phase PHASE4 · RECRUITING · Sponsor: Weill Medical College of Cornell University
A Study to Evaluate ALN-2232 in Participants With Obesity
Phase PHASE1/PHASE2 · RECRUITING · Sponsor: Alnylam Pharmaceuticals
Multi-Site Trial of Tirzepatide for Smoking Cessation
Phase PHASE2 · RECRUITING · Sponsor: University of Southern California
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: National Taiwan University Clinical Trial Center
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Phase PHASE4 · NOT_YET_RECRUITING · Sponsor: Yunlong Wang
Effects of GLP-1 RAs on Human Lactation Outcomes
Phase N/A · RECRUITING · Sponsor: University of Colorado, Denver
Salivary Function and Dental Changes During GLP-1 Therapy
Phase N/A · NOT_YET_RECRUITING · Sponsor: Bilecik Seyh Edebali Universitesi
PubMed (12)
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Jul 22 · DOI: 10.1111/obr.70198
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism · 2026 Jul · DOI: 10.1002/edm2.70291
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1834580
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100300
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Appetite · 2026 Jul 23 · DOI: 10.1016/j.appet.2026.108723